MedImmune Ventures

MedImmune Ventures functions as a corporate venture capital fund specializing in strategic equity investments within the life sciences sector. It primarily targets early to late-stage private companies engaged in biotechnology and pharmaceuticals, with a particular focus on novel therapeutics, including both small and large molecules. The fund employs an evergreen investment model, aiming to support scientific breakthroughs and foster innovation across the biopharmaceutical landscape.

The venture arm was founded in 2002 by David M. Mott, who was then the Chief Executive Officer of MedImmune. Mott established MedImmune Ventures to serve as a strategic extension of its parent company, leveraging MedImmune's deep industry expertise and financial backing. His insight was to create a mechanism for MedImmune to identify and nurture external innovations that aligned with and could significantly advance its core biologics research and development pipeline.

MedImmune Ventures provides capital and strategic partnership to its portfolio of innovative biotech and pharmaceutical startups. The fund seeks to accelerate the development and commercialization of promising new therapies and technologies. Its overarching vision is to drive meaningful medical innovation that ultimately leads to improved patient outcomes and contributes to the advancement of global health.